Skip to content

Assessment of Intracellular Cytokines and Markers in Cells (Phase 3)

Assessment of Levels of Intracellular Cytokines and Markers in Cells Recovered From the Anterior Eye (Phase 3)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03896100
Enrollment
12
Registered
2019-03-29
Start date
2019-03-28
Completion date
2019-09-15
Last updated
2019-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impression Cytology

Brief summary

This is a single arm, prospective, bilateral, non-randomized study that will be split into four elements. Element 1 will be an in vitro non-clinical study and described in the laboratory protocol. Elements 2, 3 and 4 will each be a single non-dispensing visit.

Interventions

None listed

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. They are of legal age (18 years) and capacity to volunteer. 2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent. 3. They are willing and able to follow the protocol. 4. They agree not to participate in other clinical research for the duration of this study.

Exclusion criteria

* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. They have had cataract surgery. 2. They have had corneal refractive surgery. 3. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 4. They are pregnant or breast-feeding. 5. They have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. HIV) or a history or anaphylaxis or severe allergic reactions. 6. They have taken part in any other contact lens or care solution clinical trial research, within two weeks prior to starting this study. 7. They are currently regularly (once per day or more) using oral or inhaled steroids or anti-inflammatory medications. 8. They are using any topical medications such as eye drops or ointments. 9. They are a current (i.e. within the last three months) contact lens wearer (wearing a lens in one or both eyes). 10. History of allergic reaction to sodium fluorescein or topical anesthetic. 11. They have Grade 3 or greater of any of the following ocular surface signs: corneal edema, corneal vascularization, corneal staining (white light evaluation), tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear. 12. Any active ocular infection or inflammation.

Design outcomes

Primary

MeasureTime frameDescription
Number of Cells1.5 hours duration of assessment timeThe frequency count of cells will be summarized within the category.
Types of Cells1.5 hours duration of assessment timeThe percentage of types of cells will be summarized within the category.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026